ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,780Medicare Part D Prescriptions Filled, Including Refills

Rank: 307 out of 780

$597K Total Retail Price of All Prescriptions

Rank: 231 out of 780

483 Patients Receiving at Least One Drug in Part D
78%Patients 65 Years and Older
70% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Alabama
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

17% of this provider’s 483 patients filled at least one prescription for a schedule three drug, compared to an average of 19%.

Risky Drugs to Seniors

2% of this provider’s 8,116 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$61 was the average price of a prescription from this provider, compared to $51 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 23.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Alabama
LEVOTHYROXINE SODIUM 369 314 1 5
AMLODIPINE BESYLATE 323 295 2 4
HYDROCODONE-ACETAMINOPHEN 278 240 S3 3 1
TRAMADOL HCL 275 233 4 15
FUROSEMIDE 266 241 5 7
OMEPRAZOLE 216 159 6 3
PANTOPRAZOLE SODIUM 207 198 7 25
LISINOPRIL 205 155 8 6
SIMVASTATIN 182 147 9 2
MELOXICAM 179 170 10 16
POTASSIUM CHLORIDE 177 158 11 11
PRAVASTATIN SODIUM 168 137 12 9
ZOLPIDEM TARTRATE 148 102 13 17
DONEPEZIL HCL 148 142 13 31
LYRICA 140 92 15 52
METOPROLOL SUCCINATE 136 117 16 20
WARFARIN SODIUM 134 130 17 24
GABAPENTIN 133 114 18 13
LOSARTAN POTASSIUM 132 112 19 18
NEXIUM 123 103 20 22
SERTRALINE HCL 116 88 21 27
METFORMIN HCL 114 82 22 8
METOPROLOL TARTRATE 108 102 23 19
CITALOPRAM HBR 108 100 23 23
CARVEDILOL 101 86 25 14
HYDROCHLOROTHIAZIDE 99 73 26 10
PAROXETINE HCL 89 76 27 69
RISPERIDONE 80 80 28 98
LANTUS 79 69 29 71
QUETIAPINE FUMARATE 76 73 30 81
SYNTHROID 76 47 30 77
CYMBALTA 74 72 32 51
POLYETHYLENE GLYCOL 3350 74 62 32 79
NAMENDA 73 73 34 46
DIGOXIN 71 65 35 56
TRAZODONE HCL 68 59 36 35
ATENOLOL 67 52 37 21
CLONIDINE HCL 67 54 37 28
IPRATROPIUM-ALBUTEROL 63 62 39 214
LEVOFLOXACIN 61 55 40 76
ATORVASTATIN CALCIUM 57 43 41 12
CRESTOR 56 52 42 32
PLAVIX 56 43 42 45
HYDROXYZINE HCL 55 55 R 44 155
CLOPIDOGREL 53 49 45 34
EXELON 51 51 46 132
NITROFURANTOIN 51 51 46 235
DIVALPROEX SODIUM 50 46 48 119
MIRTAZAPINE 50 50 48 58
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 31, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.